Winning Stock Forecast: Destination Maternity Corp. Turns Management Around and Returns up to 161.73% in 3 Months

“I’ve failed over and over and over again in my life and that is why I succeed.” 

-Michael Jordan

(Source: Wikipedia)

Destination Maternity Corporation is a maternity apparel designer and retailer. Incorporated on October 23, 1980, the company operates over 1815 retail locations between the United States and England. The company also sells its merchandise through it’s Canadian website, MotherhoodCanada.ca, and through Amazon.com.

On March 22nd, I Know First gave a bullish 3 month forecast for DEST. Over that 3 month period, DEST saw a return of up to 161.73%.

<span style="font-weight

Read More

Winning SIG Forecast: Signet Jewelers Is A Diamond In The Rough

The Path to Brilliance plan “is intended to reposition Signet to be a share-gaining OmniChannel jewelry category leader.

– Signet Chief Executive Officer Virginia Dossos

(Source: Wikimedia Commons)

Signet Jewelers Ltd. (NYSE: SIG) is one of the biggest diamond jewelry retailers and is the parent company of many smaller jewelry chains such as Jared, Zales, Kay, and more. On June 6, the I Know First algorithm issued a bullish

Read More

Quick Win by the Algorithm: Stein Mart, Inc. (NASDAQ: SMRT) Returns up to 230.21% in 3 Months

“Fashion is part of the daily air and it changes all the time, with all the events. You can even see the approaching of a revolution in clothes. You can see and feel everything in clothes.”

– Diana Vreeland

(Source: Flickr)

Stein Mart, Inc. is a national discount retailer offering fashion merchandise, services, and presentations of a department or specialty store. The company sells clothes, accessories, and home fashion to both men and women. The company’s target audience are women over 45 with household income of around $100,000 a year. Incorporated

Read More

Winning FOSL Stock Forecast: Fossil Group shows great comeback after loss in 2018

Winning FOSL Stock Forecast: Fossil Group shows great comeback in 2018 

“We had an encouraging start to the year, delivering first quarter sales results that were stronger than our expectations. This performance reflects the disciplined execution of our strategy which capitalizes on our strong design, innovation, distribution and operating capabilities.

-Kosta Kartsotis, Chairman and CEO

(Source: Wikimedia Commons)

Fossil Group, Inc., incorporated on December 26, 1991, is a design, marketing and distribution company that specializes in consumer fashion accessories. The Company’s segments include Americas, Europe and Asia. Each segment includes sales to

Read More

Winning AAXN Stock Forecast: Axon Enterprise’s Business Continues to Expand as They Acquire VieVu

“We’re up against little companies like Motorola and Panasonic and L3, so there’s still a lot of competition, but the fact is we’ve been winning the vast majority of the deals because our system performs really well.” – Rick Smith, Co-founder and CEO of Axon Enterprise, Inc.

Axon Enterprise, Inc., (NASDAQ: AAXN) formerly TASER International Inc., is engaged in development, manufacture and sale of conducted electrical weapons (CEWs) as well as development of connected wearable on-officer cameras for use by law enforcement

Read More

Winning CHK Stock Forecast: Chesapeake Energy Stock Posts Gains of 26.11% in 7 Days

“The underlying strength of our operations, coupled with higher realized prices, resulted in our best financial performance since before the downturn in 2014. For the second consecutive quarter, we recorded significant growth in our earnings and cash flow. ”

-Doug Lawler, Chesapeake’s Chief Executive Officer

(Source: Glassdoor)

Last week, Chesapeake Energy Corporation (NYSE: CHK) jumped from $3.6 at closing on May 14 and closed at $4.54 on May 22, a solid 26.11% gain. Overall, the stock has gained over 50% in the last 3 months whereas

Read More

Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility

Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility

[Source: Live Trading News, May 23, 2018]

“Already, this year to-date, we have achieved multiple successes with our pipeline of Nektar invented medicines across three therapeutic areas, immuno-oncology, immunology and pain. In the area of chronic pain, we will submit the NDA for NKTR-181 to the FDA this month”

— Howard Robin – President and CEO of Nektar Therapeutics

Summary

  • Over the past year  NKTR went up 340.47%
  • They are one of the most robust growers investors more so during the past 12 months – due to many catalysts powering the firm.
  • Nektar recently commenced the phase 1B study of NKTR-358 for systemic lupus erythematosus.
  • If the mentioned drug can post robust clinical outcomes as prognosticated, it can cut into the $45.5B autoimmune diseases market to deliver significantly more upsides for Nektar.

Over the past year, from May 21 2017 through May 21 2018, NKTR produced a whopping 340.47% return to investors. Nektar Therapeutics is one of the most robust growers investors

Read More